Teva Pharmaceutical Industries Ltd ADR
TEVA: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$36.00 | Gtgh | Rtnnpjxc |
Teva Is Benefiting From Rationalized Portfolio, Optimized Pipeline, and New Branded Drug Launches
We are setting a fair value estimate of $10.50 per share for Teva Pharmaceutical, and we don't believe Teva has an established an economic moat. Our ten-year forecast lies on a low-single digit top line growth with a slight improvement in margin until 2029 when we start to expect difficult landscapes for its branded drugs.